Sodium/glucose cotransporter
From Proteopedia
(Difference between revisions)
(New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> This is a default text for you...) |
|||
| Line 1: | Line 1: | ||
| - | + | ||
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
This is a default text for your page '''Sodium/glucose cotransporter'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | This is a default text for your page '''Sodium/glucose cotransporter'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
| Line 5: | Line 5: | ||
== Function == | == Function == | ||
| + | |||
| + | '''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT2 is responsible of renal glucose absorption <ref>PMID:32796035</ref>. | ||
== Disease == | == Disease == | ||
| Line 10: | Line 12: | ||
== Relevance == | == Relevance == | ||
| - | SGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and | + | SGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and COPD<ref>PMID:36819350</ref>.. |
== Structural highlights == | == Structural highlights == | ||
Revision as of 07:18, 15 April 2024
| |||||||||||
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
- ↑ Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020 Oct 16;295(42):14379-14390. PMID:32796035 doi:10.1074/jbc.REV120.008387
- ↑ Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. PMID:36819350 doi:10.7759/cureus.33939
